RISK WATCHYahoo • 2d ago
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key InsightsHumacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.
Why HUMA Stock slipped -0.06% Today — RQD Quant Desk Flash
$0.47 -0.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.47
Humacyte Inc. (HUMA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $130.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HUMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.47 (-0.06% 1D, market cap $130.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HUMA ranks #812 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HUMA compare to MOLN and CMPX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MOLN (Molecular Partners AG) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HUMA?
▼
Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue, -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.47 (-0.20%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-12.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HUMA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY HUMA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.39+2.6% Next Q
23
Q2 (-2Q)Grade E$0.40+0% Next Q
26
Q3 (-1Q)Grade E$0.40+17.5% Next Q
28
CurrentGrade E$0.47-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HUMA Turnaround Squeeze
While HUMA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.52) and Max Pain ($0.49) forces dealer call-delta covering toward $1.76.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HUMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HUMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HUMA Stock slipped -0.06% Today — RQD Quant Desk Flash
Humacyte Inc. (HUMA) slipped -0.06% to $0.47, trading at 10% of its 52-week range ($0.34 – $1.68). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($0.34 – $1.68) with RSI-14 at 51.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live HUMA Headlines & Catalysts
MARKET WIREYahoo • 4d ago
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biote
CATALYSTYahoo • 9d ago
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaning
CATALYSTBenzinga • 10d ago
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026- The presenter, Dr. Roy-Chaudhury said, "These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a
MARKET WIREYahoo • 11d ago
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market TodayHumacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
RISK WATCHYahoo • 13d ago
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteIn the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HUMA)
- ✓Walkthrough of HUMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HUMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.46%⚡ TESTING RESISTANCE
2026-11-02O $0.47H $0.47L $0.47C $0.47VOL 3.70M
RES: $0.50SUP: $0.24SMA50: $0.52SMA200: $0.80
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HUMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HUMA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HUMA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HUMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HUMA)
Health Care Rank #812 of 1016
⚔️ MOLN vs HUMA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HUMA vs. MOLN, CMPX, CHRS, ARMP)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Humacyte Inc. (HUMA) ranks #812 by composite RQD confidence (31/100, grade E) and #628 by equity capitalization ($130.5M). Within this direct 5-issuer industry benchmark cohort, HUMA leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HUMA at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HUMA
ACTIVE
Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -0.06% | $130.5M | Benchmark Subject |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | -4.88% | $132.4M | /moln-vs-huma → |
| CMPX Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | -0.54% | $136.2M | /cmpx-vs-huma → |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -22.55% | $138.8M | /chrs-vs-huma → |
| ARMP Armata Pharmaceuticals Inc. | D- | 43/100 | — | — | -35.0% | -1.22% | $120.8M | /armp-vs-huma → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818382In its most recent audited fiscal period (FY2025, filed 2025-12-31), Humacyte Inc. (HUMA) reported GAAP revenue of $2.0M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$40.8M, operating cash flow of -$105.0M, and free cash flow of -$105.9M (-6.3% YoY). On the balance sheet, HUMA closed FY2025 with $116.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.0M | -$40.8M | -$105.0M | -$105.9M | $116.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$148.7M | -$98.1M | -$99.7M | $137.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$110.8M | -$73.3M | -$73.3M | — | — |
3. HUMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.47 (-0.06% 1D, market cap $130.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HUMA ranks #812 in composite RQD confidence.
How does HUMA compare to MOLN and CMPX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MOLN (Molecular Partners AG) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HUMA?
Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue, -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HUMA trading relative to its 50-day, 200-day, and 52-week technical levels?
HUMA last traded at $0.47 (-0.06% on volume of 3,704,487 shares), positioning the stock -9.62% below its 50-day simple moving average ($0.52) and -41.25% below its 200-day simple moving average ($0.80). Across its 52-week range of $0.34 to $1.68, HUMA sits at the 9.7% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).
HUMA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HUMA stock moving today?
Why HUMA Stock slipped -0.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.